Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC Vaccine + CIK Cells in Extensive-Stage SCLC
NCT02688673Phase 2Unknown
- Sponsor
- Academy of Military Medical Sciences
- Start
- Aug 2014
- Primary completion
- Aug 2016
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
A Phase 2 trial of adenovirus-transfected autologous dendritic cell vaccine (MUC1/Survivin) in small cell lung cancer (SCLC), sponsored by Academy of Military Medical Sciences. Status: unknown.
02
Drugs
adenovirus-transfected autologous dendritic cell vaccine (MUC1/Survivin)
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02688673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02688673.